Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Children's Hospital/USC School of Medicine
15
mi
from 91732
Los Angeles, CA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Children's Hospital/USC School of Medicine
15
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Children's Hospital and Research Center
352
mi
from 91732
Oakland, CA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Children's Hospital and Research Center
352
mi
from 91732
Oakland, CA
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
UCSD/San Diego Children's Hospital
106
mi
from 91732
San Diego, CA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
UCSD/San Diego Children's Hospital
106
mi
from 91732
San Diego, CA
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Diabetes Center at UCSF
41
mi
from 91732
San Francisco, CA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Diabetes Center at UCSF
41
mi
from 91732
San Francisco, CA
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Barbara Davis Center for Childhood Diabetes, University of Colorado
824
mi
from 91732
Aurora, CO
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Barbara Davis Center for Childhood Diabetes, University of Colorado
824
mi
from 91732
Aurora, CO
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Emory Children's Center
1922
mi
from 91732
Atlanta, GA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Emory Children's Center
1922
mi
from 91732
Atlanta, GA
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Univ of Minnesota
1511
mi
from 91732
Minneapolis, MN
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Univ of Minnesota
1511
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
Children's Mercy Hospital
1341
mi
from 91732
Kansas City, MO
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
Children's Mercy Hospital
1341
mi
from 91732
Kansas City, MO
Click here to add this to my saved trials
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated:  1/15/2016
University of Pennsylvania/Children's Hospital of Philadelphia
2375
mi
from 91732
Philadelphia, PA
Study of Antithymocyte Globulin for Treatment of New-onset T1DM
Effect of Antithymocyte Globulin on Preserving Beta Cell Function in New Onset Type 1 Diabetes Mellitus
Status: Enrolling
Updated: 1/15/2016
University of Pennsylvania/Children's Hospital of Philadelphia
2375
mi
from 91732
Philadelphia, PA
Click here to add this to my saved trials
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated:  1/15/2016
Anthony Jordan Health Center
2246
mi
from 91732
Rochester, NY
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated: 1/15/2016
Anthony Jordan Health Center
2246
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated:  1/15/2016
Rochester General Medical Associates
2246
mi
from 91732
Rochester, NY
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated: 1/15/2016
Rochester General Medical Associates
2246
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated:  1/15/2016
Unity Health System
2241
mi
from 91732
Rochester, NY
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated: 1/15/2016
Unity Health System
2241
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated:  1/15/2016
Westside Health Services
2245
mi
from 91732
Rochester, NY
Comparing Diabetes Prevention Programs
Comparative Effectiveness of Practice-Based Diabetes Prevention Programs - A Pilot Study
Status: Enrolling
Updated: 1/15/2016
Westside Health Services
2245
mi
from 91732
Rochester, NY
Click here to add this to my saved trials
Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500
A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin R U-500 and Humalog Mix 75/25 in Subjects With Type 2 Diabetes Mellitus Who Are Treated With 50-200 Units of Insulin Per Day
Status: Enrolling
Updated:  1/15/2016
Profil Institute for Clinical Research
115
mi
from 91732
Chula Vista, CA
Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500
A Single-blind Crossover Study of the Pharmacokinetic and Postprandial Glucose Dynamics of BIOD-531 Compared to Humulin R U-500 and Humalog Mix 75/25 in Subjects With Type 2 Diabetes Mellitus Who Are Treated With 50-200 Units of Insulin Per Day
Status: Enrolling
Updated: 1/15/2016
Profil Institute for Clinical Research
115
mi
from 91732
Chula Vista, CA
Click here to add this to my saved trials
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Status: Enrolling
Updated:  1/19/2016
Indiana Clinical Research Center
1793
mi
from 91732
Indianapolis, IN
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Modulation of Human Myocardial Metabolism by GLP-1 Dose Response
Status: Enrolling
Updated: 1/19/2016
Indiana Clinical Research Center
1793
mi
from 91732
Indianapolis, IN
Click here to add this to my saved trials
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated:  1/19/2016
Novartis Investigative Site
2435
mi
from 91732
New York City, NY
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated: 1/19/2016
Novartis Investigative Site
2435
mi
from 91732
New York City, NY
Click here to add this to my saved trials
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated:  1/19/2016
Novartis Investigative Site
965
mi
from 91732
Seattle, WA
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated: 1/19/2016
Novartis Investigative Site
965
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated:  1/19/2016
Novartis Investigative Site
965
mi
from 91732
Seattle, WA
Study of Secukinumab in Patients With Newly-diagnosed Type 1 Diabetes Mellitus
A Randomized, Double-blind, Multiple Dose, Placebo-controlled Study to Evaluate the Safety, Tolerability, Immunogenicity, Pharmacokinetics, and Efficacy of Secukinumab in Adult and Pediatric Patients With New-onset Type 1 Diabetes Mellitus(T1D)
Status: Enrolling
Updated: 1/19/2016
Novartis Investigative Site
965
mi
from 91732
Seattle, WA
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Endocrinology Associates
1829
mi
from 91732
Montgomery, AL
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Endocrinology Associates
1829
mi
from 91732
Montgomery, AL
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Diabetes and Endocrine Consultants P.C.
1829
mi
from 91732
Montgomery, AL
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Diabetes and Endocrine Consultants P.C.
1829
mi
from 91732
Montgomery, AL
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
University of Miami, Diabetes Research Institute
2320
mi
from 91732
Miami, FL
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
University of Miami, Diabetes Research Institute
2320
mi
from 91732
Miami, FL
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Dr. Rife and Associates Family Medicine
1716
mi
from 91732
Orland Park, IL
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Dr. Rife and Associates Family Medicine
1716
mi
from 91732
Orland Park, IL
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Highland Clini-Endocrinology
1401
mi
from 91732
Shreveport, LA
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Highland Clini-Endocrinology
1401
mi
from 91732
Shreveport, LA
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Annapolis Internal Medicine LLC
2309
mi
from 91732
Annapolis, MD
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Annapolis Internal Medicine LLC
2309
mi
from 91732
Annapolis, MD
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Nallin Family Healthcare
2185
mi
from 91732
Cumberland, MD
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Nallin Family Healthcare
2185
mi
from 91732
Cumberland, MD
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Center for Diabetes and Endocrinology
2591
mi
from 91732
Portsmouth, NH
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Center for Diabetes and Endocrinology
2591
mi
from 91732
Portsmouth, NH
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
North Country Community Physicians
2451
mi
from 91732
Glen Cove, NY
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
North Country Community Physicians
2451
mi
from 91732
Glen Cove, NY
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Great Neck Medical Group
2446
mi
from 91732
Great Neck, NY
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Great Neck Medical Group
2446
mi
from 91732
Great Neck, NY
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
North Shore Diabetes and Endocrine Associates
2448
mi
from 91732
New Hyde Park, NY
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
North Shore Diabetes and Endocrine Associates
2448
mi
from 91732
New Hyde Park, NY
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Mountain Diabetes & Endocrine Center
2005
mi
from 91732
Asheville, NC
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Mountain Diabetes & Endocrine Center
2005
mi
from 91732
Asheville, NC
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Primary Care Wakefield
2559
mi
from 91732
Wakefield, RI
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Primary Care Wakefield
2559
mi
from 91732
Wakefield, RI
Click here to add this to my saved trials
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated:  1/19/2016
Endocrinology Associates Inc.
2133
mi
from 91732
Roanoke, VA
Patient Transitioning From Exubera® Inhalation Powder to Technosphere® Insulin Inhalation Powder
Patient Transfer Program for Transitioning From Exubera® (Insulin Human [rDNA Origin]) Inhalation Powder to Technosphere® Insulin (Insulin Human [rDNA Origin]) Inhalation Powder
Status: Enrolling
Updated: 1/19/2016
Endocrinology Associates Inc.
2133
mi
from 91732
Roanoke, VA
Click here to add this to my saved trials
Empowering Rural African American Women and Communities to Improve Diabetes Outcomes
Empowering Rural African American Women and Communities to Improve Diabetes Outcomes
Status: Enrolling
Updated:  1/19/2016
East Carolina University
2290
mi
from 91732
Greenville, NC
Empowering Rural African American Women and Communities to Improve Diabetes Outcomes
Empowering Rural African American Women and Communities to Improve Diabetes Outcomes
Status: Enrolling
Updated: 1/19/2016
East Carolina University
2290
mi
from 91732
Greenville, NC
Click here to add this to my saved trials
Text Messaging for Weight Loss
The Comparative Effectiveness of Clinic-Based Weight Loss Strategies
Status: Enrolling
Updated:  1/19/2016
Denver Health
816
mi
from 91732
Denver, CO
Text Messaging for Weight Loss
The Comparative Effectiveness of Clinic-Based Weight Loss Strategies
Status: Enrolling
Updated: 1/19/2016
Denver Health
816
mi
from 91732
Denver, CO
Click here to add this to my saved trials
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
Status: Enrolling
Updated:  1/21/2016
Novo Nordisk Clinical Trial Call Center
1505
mi
from 91732
Minneapolis, MN
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
A Trial Comparing the Efficacy of Insulin Degludec With Insulin Glargine on Glycaemic Control Using Continuous Glucose Monitoring in Patients With Type 1 Diabetes
Status: Enrolling
Updated: 1/21/2016
Novo Nordisk Clinical Trial Call Center
1505
mi
from 91732
Minneapolis, MN
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
1784
mi
from 91732
Birmingham, AL
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
1784
mi
from 91732
Birmingham, AL
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
1784
mi
from 91732
Birmingham, AL
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1276.1.10044 Boehringer Ingelheim Investigational Site
2468
mi
from 91732
Hot Springs, AK
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1276.1.10044 Boehringer Ingelheim Investigational Site
2468
mi
from 91732
Hot Springs, AK
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1301.1.5727 Boehringer Ingelheim Investigational Site
336
mi
from 91732
Glendale, AZ
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1301.1.5727 Boehringer Ingelheim Investigational Site
336
mi
from 91732
Glendale, AZ
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1276.1.10035 Boehringer Ingelheim Investigational Site
1491
mi
from 91732
Searcy, AR
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1276.1.10035 Boehringer Ingelheim Investigational Site
1491
mi
from 91732
Searcy, AR
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1218.64.10007 Boehringer Ingelheim Investigational Site
112
mi
from 91732
Chula Vista, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1218.64.10007 Boehringer Ingelheim Investigational Site
112
mi
from 91732
Chula Vista, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1222.29.11006 Boehringer Ingelheim Investigational Site
27
mi
from 91732
Huntington Beach, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1222.29.11006 Boehringer Ingelheim Investigational Site
27
mi
from 91732
Huntington Beach, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1245.19.10047 Boehringer Ingelheim Investigational Site
106
mi
from 91732
La Mesa, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1245.19.10047 Boehringer Ingelheim Investigational Site
106
mi
from 91732
La Mesa, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
13
mi
from 91732
Los Angeles, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
13
mi
from 91732
Los Angeles, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
13
mi
from 91732
Los Angeles, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1220.48.0018 Boehringer Ingelheim Investigational Site
70
mi
from 91732
Oceanside, CA
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1220.48.0018 Boehringer Ingelheim Investigational Site
70
mi
from 91732
Oceanside, CA
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1268.17.01015 Boehringer Ingelheim Investigational Site
802
mi
from 91732
Colorado Springs, CO
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1268.17.01015 Boehringer Ingelheim Investigational Site
802
mi
from 91732
Colorado Springs, CO
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
Boehringer Ingelheim Investigational Site
817
mi
from 91732
Denver, CO
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
Boehringer Ingelheim Investigational Site
817
mi
from 91732
Denver, CO
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1245.20.10038 Boehringer Ingelheim Investigational Site
823
mi
from 91732
Northglenn, CO
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1245.20.10038 Boehringer Ingelheim Investigational Site
823
mi
from 91732
Northglenn, CO
Click here to add this to my saved trials
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  1/22/2016
1245.23.10042 Boehringer Ingelheim Investigational Site
2315
mi
from 91732
Fort Lauderdale, FL
Safety and Efficacy Study of Empagliflozin and Metformin for 24 Weeks in Treatment Naive Patients With Type 2 Diabetes
A 24-week Phase III Randomized, Double-blind, Parallel Group Study to Evaluate the Efficacy and Safety of Twice Daily Oral Administration of Empagliflozin + Metformin Compared With the Individual Components of Empagliflozin or Metformin in Drug Naive Patients With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 1/22/2016
1245.23.10042 Boehringer Ingelheim Investigational Site
2315
mi
from 91732
Fort Lauderdale, FL
Click here to add this to my saved trials